Generali Asset Management SPA SGR Acquires 8,288 Shares of AbbVie Inc. $ABBV

Generali Asset Management SPA SGR lifted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 10.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 86,410 shares of the company's stock after purchasing an additional 8,288 shares during the period. Generali Asset Management SPA SGR's holdings in AbbVie were worth $19,744,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Climber Capital SA bought a new position in shares of AbbVie in the 4th quarter worth approximately $205,000. Luken Investment Analytics LLC lifted its stake in shares of AbbVie by 70.2% in the 4th quarter. Luken Investment Analytics LLC now owns 143 shares of the company's stock worth $33,000 after purchasing an additional 59 shares during the period. ASR Vermogensbeheer N.V. raised its stake in AbbVie by 1.1% during the 4th quarter. ASR Vermogensbeheer N.V. now owns 182,862 shares of the company's stock worth $41,782,000 after acquiring an additional 2,038 shares during the period. MGO One Seven LLC raised its stake in AbbVie by 9.5% during the 4th quarter. MGO One Seven LLC now owns 84,439 shares of the company's stock worth $19,293,000 after acquiring an additional 7,346 shares during the period. Finally, Eclectic Associates Inc. ADV raised its stake in AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company's stock worth $1,337,000 after acquiring an additional 45 shares during the period. Institutional investors own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and top-line growth reassure investors that AbbVie’s business is diversifying beyond Humira; EPS was $2.65 vs. $2.59 expected and revenue was $15.0B, supporting the long‑term dividend thesis. AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
• Positive Sentiment: Pipeline progress: AbbVie completed a Phase 1a safety study for ABBV‑142 — a near‑term de‑risking event that nudges pipeline expectations higher if later efficacy readouts follow. AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher
• Positive Sentiment: SKYRIZI and RINVOQ momentum: reimbursement wins (e.g., Canada) and label/clinical expansions are reinforcing the growth narrative that could offset legacy biologic declines. Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
• Neutral Sentiment: Management will present at the Bank of America Healthcare Conference on May 13 — a scheduled event where investors will look for color on guidance, pipeline timelines and M&A strategy. AbbVie to Present at the Bank of America Securities Healthcare Conference
• Neutral Sentiment: Industry readouts (DDW 2026) and analysts’ earnings‑call questions are prompting close scrutiny of clinical data and commercialization plans — items that could swing sentiment after more detail is released. DDW 2026: key readouts from the conference 5 must-read analyst questions from AbbVie’s Q1 earnings call
• Negative Sentiment: Valuation and technicals are headwinds: ABBV trades with a high P/E (~99.8) and recently hit a 1‑year high, encouraging profit‑taking; trading volume is slightly below average, suggesting thinner support on the pullback. (Background market data)
• Negative Sentiment: Accounting/metric oddities (very negative ROE) and any upcoming clinical/competitive setbacks could amplify downside risk if investors reassess growth sustainability and capital allocation. (Background market data)

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company's stock.

AbbVie Price Performance

Shares of ABBV opened at $202.59 on Friday. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The company has a 50 day simple moving average of $213.18 and a two-hundred day simple moving average of $221.00. The firm has a market cap of $358.21 billion, a P/E ratio of 99.80, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the firm posted $2.46 EPS. The company's revenue was up 12.4% on a year-over-year basis. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 340.89%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. DZ Bank upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday, April 30th. Bank of America upgraded shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price on the stock in a research note on Thursday, April 30th. Guggenheim restated a "buy" rating and set a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 4th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $252.90.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.